TrovaGene Inc  

(Public, NASDAQ:TROVU)   Watch this stock  
Find more results for TROVU
22.60
0.00 (0.00%)
Jul 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 14.11 - 32.69
Open     -
Vol / Avg. 0.00/85.00
Mkt cap 233.19M
P/E     -
Div/yield     -
EPS -0.92
Shares 1.67M
Beta -402.56
Inst. own 420%
Aug 10, 2015
Q2 2015 Trovagene Inc Earnings Call - 5:00PM EDT - Add to calendar
Aug 10, 2015
Q2 2015 Trovagene Inc Earnings Release - 4:00PM EDT - Add to calendar
Jul 8, 2015
Trovagene Inc at Cantor Fitzgerald Inaugural Healthcare Conference
Jun 10, 2015
Trovagene Inc Annual Shareholders Meeting
May 5, 2015
Q1 2015 Trovagene Inc Earnings Call
May 5, 2015
Q1 2015 Trovagene Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -5650.45% -5112.96%
Operating margin -3818.03% -5334.13%
EBITD margin - -5250.32%
Return on average assets -77.02% -51.11%
Return on average equity -180.50% -99.85%
Employees 31 -
CDP Score - -

Address

11055 Flintkote Ave
SAN DIEGO, CA 92121-1220
United States - Map
+1-858-2175420 (Phone)
+1-858-2174768 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Trovagene, Inc. is a development-stage molecular diagnostic company that focuses on the development and commercialization of urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. The Company's primary internal focus is to leverage its urine-based molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. Its cell-free BRAF test confirms the presence of a BRAF V600E mutation in urine DNA at levels of greater than or equal to 0.03% in comparison to the wild-type BRAF genes. Its KRAS mutation assay detects and monitors the seven commonly encountered mutations of the KRAS oncogene. Its urine-based Human Papilloma Virus (HPV) assay identifies women with high grade cervical intraepithelial neoplasia (CIN2/3).

Officers and directors

Thomas H. Adams Jr., Ph.D. Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Antonius P. Schuh Ph.D. Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Stephen L. Zaniboni Chief Financial Officer
Bio & Compensation  - Reuters
Matthew L. Posard Executive Vice President & Chief Commercial Officer
Age: 47
Bio & Compensation  - Reuters
Carl B. Feldbaum Esq Director
Age: 71
Bio & Compensation  - Reuters
Paul R. Billings M.D., Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
John P. Brancaccio Independent Director
Age: 67
Bio & Compensation  - Reuters
Gary S. Jacob Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Rodney S. Markin M.D., Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters